Top Buy
| Security | Buy | Sell | Buy (1M) | Sell (1M) | Price ▲ | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Bayer AG | 15 | 1 | 0 | 0 | €28.15 | €50.00 | 77.620% |
| Knight Therapeutics | 1 | 0 | 0 | 0 | €3.88 | €10.00 | 157.732% |
| Adverum Biotechnologies Inc. | 6 | 1 | 2 | 0 | €1.38 | €4.66 | 237.768% |
| ProQR Therapeutics N.V. | 6 | 0 | 1 | 0 | €1.87 | €2.81 | 50.283% |
| Xenon Pharmaceuticals Inc. | 1 | 1 | 0 | 0 | €40.80 | €50.00 | 22.549% |
| Uniqure B.V. | 1 | 0 | 1 | 0 | €4.24 | - | - |
| Enlivex Therapeutics Ltd. | 1 | 0 | 1 | 0 | €1.46 | - | - |
| Axsome Therapeutics Inc | 2 | 0 | 0 | 0 | €69.50 | €100.00 | 43.885% |
| Purple Biotech Ltd. ADR | 5 | 0 | 1 | 0 | €0.48 | €9.21 | 1802.273% |
| Rhythm Pharmaceuticals | 14 | 0 | 2 | 0 | €40.60 | €46.19 | 13.756% |
| Nektar Therapeutics | 3 | 1 | 1 | 0 | €1.46 | €3.70 | 152.732% |
| Merck & Co. Inc. | 28 | 1 | 3 | 0 | €118.60 | €124.92 | 5.331% |
| Catalyst Pharmaceutical Partners Inc | 10 | 0 | 0 | 0 | €14.00 | €23.46 | 67.599% |
| Novo Nordisk A/S | 4 | 0 | 0 | 0 | €185.00 | €182.50 | -1.351% |
| Trinity Biotech ADR | 22 | 0 | 1 | 0 | €0.41 | - | - |
| Immutep LTD ADR | 1 | 0 | 0 | 0 | €2.52 | €4.00 | 58.730% |
| Verastem Inc. | 9 | 0 | 0 | 0 | €10.20 | €27.03 | 165.010% |
| Xeris Biopharma Holdings Inc. | 4 | 0 | 0 | 0 | €1.75 | €4.39 | 150.645% |
| Abbott Laboratories | 16 | 0 | 3 | 0 | €98.38 | €116.81 | 18.731% |
| UCB S.A. | 2 | 0 | 0 | 0 | €120.70 | - | - |
| Perrigo Co. plc | 3 | 0 | 1 | 0 | €30.83 | €35.99 | 16.722% |
| Vertex Pharmaceuticals Inc. | 40 | 2 | 4 | 0 | €372.60 | €382.71 | 2.712% |
| GSK plc | 1 | 0 | 0 | 0 | €20.21 | - | - |
| Cytokinetics Inc. | 24 | 1 | 3 | 0 | €61.00 | €83.81 | 37.401% |
| Halozyme Therapeutics Inc. | 13 | 0 | 2 | 0 | €37.15 | €53.50 | 43.998% |